（於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 調整2025 年部分日常關聯交易預計的公告》，僅供參閱。 承董事會命 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 证券代码：600196 股票简称：复星医药 编号：临 2025-167 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 0 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、C ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年第三季度報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 0 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 上海复 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《第十 屆董事會第十三次會議（定期會議）決議公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 证券代码：600196 股票简称：复星医药 编号：临 2025-165 上海复星医药（集团）股份有限公司 第十届董事会第十三次会议（定期会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中國，上海 ...

Core Viewpoint - Fosun Pharma (600196)(02196) announced the board's decision to plan for the spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. on the Hong Kong Stock Exchange [1] Group 1: Company Overview - Fosun Antigen was established in July 2012 and is primarily focused on the research, production, and sales of human vaccines [1] - As of the announcement date, Shanghai Fosun Pharma Industry Development Co., Ltd. holds a 70.08% stake in Fosun Antigen, while 17 other shareholders own the remaining 29.92% [1] Group 2: Product Development - Fosun Antigen has developed a technical platform for both bacterial and viral vaccines [1] - The company has received approval for several self-developed human vaccines in mainland China, including rabies vaccines (Vero cell), lyophilized rabies vaccines (Vero cell), trivalent influenza virus split vaccine, and quadrivalent influenza virus split vaccine [1] - The 13-valent pneumococcal conjugate vaccine is currently in Phase III clinical trials, while the lyophilized rabies vaccine (human diploid cells) and 24-valent pneumococcal polysaccharide vaccine are in Phase I clinical trials [1] - The 23-valent pneumococcal polysaccharide vaccine has received approval for clinical trials [1]

Core Viewpoint - Fosun Pharma (02196) announced the board's decision to propose a spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange by October 28, 2025 [1] Company Overview - Fosun Antigen was established in July 2012 and is primarily focused on the research, development, production, and sales of human vaccines [1] - As of the announcement date, Shanghai Fosun Pharma Industrial Development Co., Ltd. holds a 70.08% stake in Fosun Antigen, while 17 other shareholders own the remaining 29.92% [1] Product Development - Fosun Antigen has developed a technical platform for both bacterial and viral vaccines [1] - The company has received approval for several self-developed human vaccines in mainland China, including: - Rabies vaccine (Vero cells) - Freeze-dried rabies vaccine (Vero cells) - Trivalent influenza virus split vaccine - Quadrivalent influenza virus split vaccine [1] - The 13-valent pneumococcal conjugate vaccine is currently in Phase III clinical trials [1] - The freeze-dried human rabies vaccine (human diploid cells) and 24-valent pneumococcal polysaccharide vaccine are in Phase I clinical trials [1] - The 23-valent pneumococcal polysaccharide vaccine has received clinical trial approval [1]

Core Viewpoint - Fosun Pharma (02196.HK) announced the board's resolution to plan for the spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. on the Hong Kong Stock Exchange by October 28, 2025 [1] Group 1: Company Overview - Fosun Antigen was established in July 2012 and is primarily focused on the research, production, and sales of human vaccines [1] - As of the announcement date, Shanghai Fosun Pharma Industrial Development Co., Ltd. holds a 70.08% stake in Fosun Antigen, while 17 other shareholders own the remaining 29.92% [1] Group 2: Product Development - Fosun Antigen has developed a technical platform for both bacterial and viral vaccines [1] - The company has received approval for several self-developed human vaccines in mainland China, including rabies vaccines (Vero cell), lyophilized rabies vaccines (Vero cell), trivalent influenza virus split vaccine, and quadrivalent influenza virus split vaccine [1] - The 13-valent pneumococcal conjugate vaccine is currently in Phase III clinical trials, while the lyophilized rabies vaccine (human diploid cells) and 24-valent pneumococcal polysaccharide conjugate vaccine are in Phase I clinical trials [1] - The 23-valent pneumococcal polysaccharide vaccine has received approval for clinical trials [1]

Core Viewpoint - The company has announced plans for a spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange, indicating a strategic move to enhance its focus on vaccine development and commercialization [1] Group 1 - The board of directors approved the proposal for the spin-off listing on October 28, 2025 [1] - Fosun Antigen was established in July 2012 and specializes in the research, production, and sales of human vaccines [1] - The company has developed technical platforms for both bacterial and viral vaccines [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 本公司股東及潛在投資者務請注意，建議分拆上市尚處於初步籌劃階段。本公司將遵守香 港聯合交易所有限公司證券上市規則（「上市規則」），並根據上市規則適時就建議分拆上市 進一步發佈相關公告。本公司概不保證建議分拆上市將會於何時、以何價格進行或完成。 因此，本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 自願公告 建議籌劃復星安特金於聯交所分拆上市 本公告乃由上海復星醫藥（ 集團）股份有限公司（「本公司」）自願作出。 2025年10月28日，本公司董事會（「董事會」）決議批准建議籌劃本公司附屬公司復星安特金 （ 成都 ）生物製藥有限公司（「復星安特金」）於香港聯合交易所有限公司（「聯交所」）的分拆上 市（「建議分拆上市」）。 復星安特金成立於2012年7月。截至本公告日期，本公 ...

Investment Overview - Fosun Pharma (600196) announced that its subsidiary, Fosun Pharma Industry, plans to invest 100 million RMB as a limited partner (LP) in a private equity investment fund, which aims to raise a total of 1 billion RMB. The fund will primarily invest in areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicinal supplements, and synthetic biology [1] Fund Structure - The investment structure includes Fosun Pharma Industry committing 10% of the fund, while Chengdu Zhongchan Phase II Fund and Chengdu High-tech Source Fund each contribute 19.7%. Chengdu Jiaozi Industry Fund contributes 14.85%, and Huaren Fang Investment collectively contributes 21.75%, with the remainder coming from other investors [1] Fund Management - The fund will be managed by China Resources Capital, with a duration of 7 years, which includes a 3-year investment period and a 4-year exit period. There is an option to extend the duration by 1 year [2] Decision-Making Mechanism - The investment committee consists of 7 members, with Fosun Pharma Industry having the right to nominate 1 member. Major decisions require the approval of more than 2/3 of the committee members [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 持續關連交易年度上限之修訂 持續關連交易年度上限之修訂 兹提述該公告，內容有關（ 其中包括 ）就本集團與復星國際及╱或其聯繫人互相提供產品 和服務訂立復星國際互供框架協議。該協議自2025年1月1日起至2025年12月31日止，為 期一年。 為滿足本集團於2025年最後一個季度的進一步業務開展需要，預期會使復星國際互供框 架協議範圍內的復星國際及╱或其聯繫人向本集團提供服務出現增量，而原預計的復星 國際及╱或其聯繫人向本集團提供服務的年度上限將不足以滿足截至2025年12月31日止 年度復星國際互供框架協議項下可能進行的相關交易之額度。因此，董事會建議復星國 際及╱或其聯繫人於 ...